Opus Genetics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
IRD Nasdaq 2830 opusgtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Opus Genetics, Inc.

Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes - Jun 26th, 2026 7:15 am
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases - Jun 16th, 2026 2:05 pm
Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target - Jun 10th, 2026 12:22 pm
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts - Jun 2nd, 2026 5:00 am
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 28th, 2026 2:01 pm
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference - May 27th, 2026 6:00 am
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst - May 25th, 2026 8:02 pm
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference - May 13th, 2026 5:00 am
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates - May 12th, 2026 6:20 am
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update - May 12th, 2026 5:00 am
Certara, Inc. (CERT) Q1 Earnings Miss Estimates - May 11th, 2026 5:45 am
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases - May 7th, 2026 2:30 pm
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study - May 7th, 2026 5:00 am
Here is Why Opus Genetics (IRD) is One of the Best Performing NASDAQ Stocks - May 5th, 2026 11:04 am
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program - May 4th, 2026 2:30 pm
Citizens Initiates Coverage of Opus Genetics (IRD) - May 1st, 2026 2:18 am
Opus Genetics to Participate in Leading Medical Conferences in May 2026 - Apr 27th, 2026 6:00 am
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting - Apr 10th, 2026 4:59 am
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital - Apr 6th, 2026 5:00 am
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026 - Mar 24th, 2026 5:00 am